标题: 美国医学权威性学报JAMA 对自闭症的综述性文章(英文) [打印本页] 作者: binfeng2000 时间: 2008-7-31 14:22 标题: 美国医学权威性学报JAMA 对自闭症的综述性文章(英文) Autism
A Review of the State of the Science for Pediatric Primary Health Care Clinicians
William J. Barbaresi, MD; Slavica K. Katusic, MD; Robert G. Voigt, MD
Arch Pediatr Adolesc Med. 2006;160:1167-1175.
ABSTRACT
Autism is a complex neurodevelopmental disorder characterized by impaired reciprocal social interaction, impaired communication, and restricted, repetitive, or stereotyped behaviors. Autism seems to affect more children than was previously believed, although this phenomenon may be due to broadening of the diagnostic criteria and increased awareness of the condition. Recent research has clearly indicated the importance of early identification, since early intensive treatment is associated with better long-term outcome. There are many controversies and competing theories about the etiology and treatment of autism, often leaving families confused about the best course of treatment and intervention. Pediatric primary health care clinicians have an important role in both the early identification and ongoing management of children with autism. It is, therefore, essential that primary care clinicians have up-to-date information about the science of autism.
Autism and related conditions in the autism spectrum have become the focus of intense interest fueled by concerns about the apparent increase in the number of children with these developmental disorders.1-2 Pediatricians have an important role in the identification and ongoing management of children with autism. This article provides pediatric clinicians with a contemporary understanding of autism, including definitions, epidemiology, initial identification, formal diagnostic approaches, medical evaluation, treatment, controversies, and caregiver support.
Autism, first described in 1943, is a complex developmental disorder characterized by severe impairment in reciprocal social interaction and communication and by a pattern of repetitive or stereotyped behavior.3-4 The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV, TR) includes autistic disorder in the broader category of pervasive developmental disorders, along with pervasive developmental disorder, not otherwise specified (PDD-NOS), Asperger's disorder, Rett's disorder, and childhood disintegrative disorder.3 Autistic disorder, PDD-NOS, and Asperger's disorder are often collectively referred to as the autism spectrum disorders (ASDs), while the term autism is used interchangeably with the DSM-IV, TR term autistic disorder. The term ASDs reflects the notion that these conditions are related and may be difficult to differentiate with current diagnostic tools.5-8 Pervasive developmental disorder, not otherwise specified is a somewhat ill-defined diagnosis of exclusion reserved for children with problems similar to those seen in autistic disorder but insufficient to meet the criteria for autistic disorder in number, severity, or age at onset.3, 6-7
The diagnostic criteria for autism require the presence of 6 symptoms from 3 categories: impaired reciprocal social interaction (at least 2 symptoms), impaired communication, and restricted, repetitive, or stereotyped behaviors (Table 1). These criteria reflect the central role of deficits in social behavior in children with ASDs.3, 9-10 One of the earliest and most important indicators of autism is the failure to develop joint attention,7, 11-12 which refers to the child's ability to share interests, pleasurable experiences, or requests by using gestures or verbal communication in combination with eye contact with another person.
There is widespread public concern about the apparent increase in autism, based on prevalence studies during the last 20 years.1, 13-17 Studies from the 1980s and early 1990s reported a prevalence of 4 to 10 per 10 000 children, whereas recent studies have reported prevalences of 30 to 50 per 10 000 children.1, 13-18 Studies that rely on administrative data for children who receive special education services have reported significant increases in prevalence from 1992 to 2001.19 A recent study in a single US county demonstrated an apparent increase in the incidence of research-identified autism among individuals 21 years of age or younger, from 5.5 per 100 000 in the 1980-1983 period to 44.9 per 100 000 in the 1995-1997 period.1 The advantage this incidence study had over previous prevalence studies was in its reporting rates of newly identified cases in the same community over many years with the use of consistent DSM-IV, TR–based research criteria for case identification. The timing of this apparent increase coincided with the introduction of broader diagnostic criteria, increased availability of educational services, and increased awareness of autism. These findings were not consistent with the hypotheses that immunization policy or the vaccine preservative thimerosal have contributed to this epidemiologic phenomenon.1, 20 A recent review also noted the absence of published literature that demonstrates increased rates of autism in children who have been immunized with vaccines containing thimerosal.20 A study from the United Kingdom also concluded that the observed increase in the rate of diagnosis of pervasive developmental disorder is likely the result of better case ascertainment rather than a true increase in autism.21
Early identification of autism is important because early intervention services may be more effective in children with autism than in children with other developmental disabilities.22 Pediatric clinicians are ideally positioned to assume this role, aided by practice guidelines for the diagnosis and management of ASDs in children.7, 23-24 A 2-level approach to autism screening and diagnosis is recommended.7 In children who fail routine developmental screening, specific screening for autism should be performed25-28 (Table 2). In children who fail specific autism screening, referral for a formal evaluation by an experienced clinician is recommended. Referral is also recommended for any child who does not babble or point or use other gestures by the age of 12 months, who uses no single words by 16 months or no spontaneous (nonecholalic) 2-word phrases by 24 months, or who experiences any loss of any language or social skills at any age.7
Deficits in joint attention differentiate infants with autism from those with mental retardation or typical development.29-32 These behaviors include deficits in the following areas: eye contact, orientation to name being called, pointing, and showing. In the toddler age group, a lack of pretend play and imitation, deficits in nonverbal communication, and disproportionate language delays differentiate autism from other developmental disorders.7 Although repetitive behaviors, stereotypic motor mannerisms, atypical sensory responses, and behavioral outbursts are generally observed in children with autism, these behaviors do not consistently differentiate autism from other developmental disorders at early ages.7
The Modified Checklist for Autism in Toddlers (M-CHAT) has been developed as an autism-specific screening tool for use in 24-month-old children (Table 2).33-36 It consists of 23 items based on parental report, which makes this checklist efficient for use in primary care settings. Other promising screening instruments include the Pervasive Developmental Disorders Screening Test–II37 and the Screening Tool for Autism in Two-Year Olds.38 For children who are 4 years or older, the Social Communication Questionnaire may be used as an autism screening instrument.7, 27-28
Children with autism can also be identified by a characteristic early developmental profile, with relative strengths in visuomotor problem solving and discrepant and disproportionate weaknesses in language.39-50 The Cognitive Adaptive Test/Clinical Linguistic and Auditory Milestone Scale (Capute Scales) provides quantitative information about a child's development in the domains of language and visuomotor problem solving and can be used efficiently for this purpose in primary care settings.51
A comprehensive, multidisciplinary assessment is required to evaluate a child for an ASD and to differentiate ASDs from other developmental disorders.5-7,12, 52 Since there are no definitive diagnostic tests, a clinical diagnosis by an expert, based on DSM-IV, TR criteria, remains the gold standard of ASD diagnosis.6-7,12, 52 The DSM-IV, TR criteria consist of a list of behaviors that are not described in detail, leaving considerable latitude for clinical judgment.3, 7, 12 Children who have been evaluated exclusively by school or early intervention staff should not be considered to have undergone a thorough diagnostic assessment. This can be confusing to both parents and pediatricians, given the existence of the explicit special education category "Autism Spectrum Disorders" (Individuals with Disabilities Education Act [IDEA] 97, Pub L No. 105-17).53 An ASD designation for special education purposes may be obtained without a clinical diagnosis of an ASD. Furthermore, children with autism or PDD-NOS often have severe cognitive, communicative, and behavioral problems that can only be assessed by a team of professionals (Table 3). The clinical diagnosis of an ASD is facilitated by the use of rating scales and direct assessment tools specifically developed for this purpose (Table 4).54-59
Approximately 60% to 75% of children with autistic disorder or PDD-NOS have cognitive skills in the mentally retarded range (standard scores <70 on formal cognitive tests).1, 3 Fewer children with PDD-NOS are likely to function in the mentally retarded range.52 Children with autism or PDD-NOS often demonstrate relative strength in visual problem-solving skills and relative weakness in language-based cognitive skills; this discrepant cognitive profile may be reflected in a significant discrepancy between verbal and performance IQ scores.3, 7, 39-50,52 Formal cognitive assessment should be completed using instruments that have been demonstrated to be appropriate60-67 (Table 5).
Similarly, formal speech and language assessment is essential because communication deficits of varying severity are always present in children with ASD.3, 7, 12 Children with ASD may have specific deficits in the social use of language, often referred to as pragmatic language.3, 7, 12 For example, a child may be able to recite long segments of dialogue from a favorite video yet not be able to use a 3-word sentence to ask for something to eat. Problems with pragmatic language are often identified only by a careful history or direct observation of the child in his or her natural environment.3, 7, 12
Social-adaptive behavioral assessments should include assessment of functional skills such as sleeping, eating, and toileting and problem behaviors such as aggression, oppositionality, and self-injury. This assessment is facilitated by the use of formal questionnaires and rating scales including, among others, the Vineland Adaptive Behavior Scales and the Scales of Independent Behavior.68-69 Formal assessments of fine and gross motor skills may be incorporated into the evaluation as indicated. Parent resources should be carefully assessed to enable the team to understand the context of the child's developmental problems and to ensure that plans are made to provide appropriate support to the family.
Every child with autism should undergo a formal audiologic evaluation, whether or not the child passed a newborn hearing screening test. In addition, children with autism are at risk of lead toxicity, given their high prevalence of putting objects in their mouths.70 Thus, periodic lead screening should be performed until pica resolves.7
Although a recognizable etiologic disorder is found in fewer than 25% of individuals with autism, attempts to establish an etiologic diagnosis to account for this clinical syndrome are important to identify diagnoses that may affect prognosis, risk of recurrence, and associated medical morbidity. A thorough history and physical examination should guide the medical diagnostic workup71-77 (Table 6). Since tuberous sclerosis accounts for up to 3% to 4% of autism cases, Wood's lamp examinations should be performed in every child with autism to detect the hypopigmented macules associated with this syndrome, especially if the child has an intercurrent seizure disorder.78 While routine head imaging (computed tomography or magnetic resonance imaging) is not recommended, recent studies have reported abnormal patterns of brain growth in individuals with autism.79 Functional imaging techniques are currently used as research tools but are not indicated in routine clinical practice.7, 80-81
Autism has been associated with many genetic syndromes, including Down syndrome, Angelman syndrome, de Lange syndrome, Smith-Magenis syndrome, and Smith-Lemli-Opitz syndrome.82-83 Seven percent to 8% of individuals with autism have fragile X syndrome.84 In addition, anomalies in almost every chromosome have been reported in individuals with autism, although more consistent linkage findings have been associated with chromosomes 2q, 7q, and 15q.85 Thus, DNA testing for fragile X syndrome and high-resolution chromosome analyses are recommended in the laboratory workup in children with autism, especially those with mental retardation, dysmorphic features, congenital anomalies, or a family history of autism or mental retardation.7, 84 Fluorescent in situ hybridization testing for specific chromosome deletions, duplications, or inversions should be considered if initial investigations produce negative results84-87 (Table 6). Even in the absence of a specific genetic diagnosis, the recurrence rate in siblings of children with autism is between 2% and 8%, increasing the risk of having a second child with autism nearly 50-fold over that in the general population.84
Although a wide range of inborn errors of metabolism have been associated with autistic behavior, less than 5% of children with autism have identifiable metabolic disorders.88-93 Thus, metabolic testing is particularly indicated when the autistic behaviors are accompanied by a history of developmental plateauing or regression; decompensation with mild illness, unusual odors, or food intolerance; failure to thrive; episodic lethargy; cyclic vomiting; seizures; coarse features; mental retardation; questionable newborn screening results; or birth outside the United States7 (Table 6).
By adulthood, about one third of individuals with autism will have at least 2 unprovoked epileptic seizures.82 Onset of seizures in individuals with autism follows a bimodal age distribution, with peaks in early childhood and adolescence.7, 94 All seizure types, including infantile spasms, can be associated with autism, but partial complex seizures, with electroencephalographic abnormalities occurring most often over the temporal lobes, appear to be most prevalent.95 About one third of parents of children with autism report regression of language in their children, most commonly the loss of their toddler's first few words, between age 18 and 24 months.94, 96 Approximately 10% of children with autism also have a paroxysmal electroencephalographic pattern similar to that seen in Landau-Kleffner syndrome (acquired epileptic aphasia) or electrical status epilepticus during slow-wave sleep.94 While there have been reports of the use of anticonvulsant therapy and even epilepsy surgery, there is insufficient evidence to recommend routine electroencephalography in all children with autism.97-99 Indications for prolonged sleep-deprived electroencephalography with adequate sampling of slow-wave sleep are listed in Table 6.7
Pediatricians have an important role in helping to guide families toward intervention approaches that have been empirically demonstrated as effective.5, 52, 100 In the Internet era, families have access to virtually limitless information about treatments and interventions for autism. Since family resources of time, energy, and finances are limited, it is essential to ensure that these resources are directed toward interventions that offer the best hope for improved outcome.
The Individuals with Disabilities Education Act mandates educational services for children in the special education category of Autism Spectrum Disorders.52 The provisions of the Individuals with Disabilities Education Act do not, however, ensure that children will receive empirically validated interventions of appropriate intensity. There is, therefore, considerable variability in the quality of educational interventions for children with ASD. This is an additional important reason for pediatricians to understand and advocate for optimal services.
Decades-worth of scientific research provide clear and convincing support for the technique referred to as Applied Behavior Analysis (ABA).5, 100 This technique uses the principles of operant conditioning to teach specific social, communicative, and behavioral skills to children with ASD.5, 100 It involves teaching new behaviors by explicit reinforcement of these behaviors; problem behaviors are often addressed by carefully analyzing triggers or antecedents of the problem behavior in order to change the factors in the environment that are contributing to the problem behavior. Applied Behavior Analysis also uses careful collection of data to demonstrate the efficacy of treatment in the individual child; the data are used to assess progress and to continually modify the intervention as the child progresses toward specific learning objectives.101
Interest in ABA as a primary, comprehensive treatment approach in children with ASD was sparked by the research of Lovaas,102-103 who reported that 9 (47%) of 19 young children with autism who received intensive, early ABA (40 hours per week for 2 years) had outcomes that were indistinguishable from their normally developing peers.103 Subsequent studies have led many experts in the field to conclude that intensive ABA is an effective intervention but that it is unlikely that 50% of children who receive early, intensive ABA will achieve completely normal developmental outcomes.100, 104-107 Practice guidelines have used these and other research findings to formulate recommendations on the key features of appropriate intervention for children with autism.5, 52, 100 Characteristics of effective intervention are believed to include a minimum of 20 hours per week of carefully organized services initiated at an early age (preferably younger than 4 years) and involving direct adult attention in individual or very small group instruction.5, 7, 52, 100 Recent studies have concluded that intensity of intervention is important (ie, a minimum of 20 hours per week) and that ABA is superior to other intervention strategies.100, 108
Another intervention model with a long history and well-defined instructional methods is TEACCH (Treatment and Education of Autistic and Related Communication Handicapped Children).109 The TEACCH approach takes advantage of relative strengths in visual information processing, characteristic of many children with ASD, using strategies such as visual schedules, clearly structured and organized classrooms, and highly structured learning activities that are broken down into manageable, visually organized steps. Published reports demonstrate improvement in behaviors and functional skills and parent satisfaction with the TEACCH approach.52, 109-110 However, there appear to be no direct studies of treatment outcomes attributable to TEACCH interventions.
While other intervention strategies are often recommended, there do not appear to be approaches that have the empirical support of ABA or the long history and well-developed curricula of TEACCH. The weight of currently available scientific evidence, however, indicates that ABA should be viewed as the optimal, comprehensive treatment approach in young children with ASD.
Pediatricians should also be aware of sensory integration therapy because this approach is often used in special education programs. Interest in sensory integration is related to the observation that children with ASD often exhibit unusual sensory responses, such as hypersensitivity to certain noises. Techniques used in this therapy include "brushing" of the skin, "swinging" to stimulate vestibular responses, and deep-pressure massage applied in an effort to calm the child.52 There is no available empirical support for sensory integration therapy, and it should, therefore, neither be routinely recommended nor viewed as a primary intervention strategy in children with ASD.5, 52
Many other unproved nonmedical therapies have been recommended for use in children with autism. There is no evidence to support the use of facilitated communication, auditory integration training, or music therapy.5, 111-115
Although psychopharmacologic therapies have been studied for more than 50 years, there are no Food and Drug Administration–approved indications for the treatment of autism with any agent and there is no medication available for treatment of the core deficits in communication and social interaction.116 In addition, when used to treat similar target behaviors, psychotropic medications tend to be less effective and result in more adverse effects when used in children with autism compared with children without autism because of similar target behavioral symptoms. However, there is an evidence base for prescribing risperidone to assist in managing tantrums, aggression, and self-injurious and stereotypic behaviors and for prescribing methylphenidate to manage inattentive, impulsive, and hyperactive behaviors in children with autism.117-118 To date, there is insufficient evidence to support the use of selective serotonin reuptake inhibitors, 2-adrenergic agonists, or mood stabilizers, despite reports of their effectiveness in managing target behavioral symptoms in some children with autism in short-term open-label trials with small sample sizes.119-121 Psychotropic medications should never be used in isolation but used only in conjunction with behavioral, educational, and habilitative therapies.122 If psychotropic medications are used, initial dosage should be low, with gradual increases in dosage until optimal positive effects, without significant adverse effects, are achieved.
Traditional medicine does not offer a cure for autism. As a result, unproved complementary and alternative treatments are often provided to children with autism by parents who are seeking effective biomedical interventions.123 Patients with chronic conditions with unclear pathophysiologic features, fluctuating courses, highly subjective symptoms, and few effective evidence-based treatments are most vulnerable to the placebo effect.124 Such is clearly the case in autism, and unproved explanations of causation and unproved therapies abound.
One example is the controversy about whether the mercury-containing compound thimerosal, which has been included in certain vaccines to protect multiple-dose vials from bacterial and fungal contamination, is related to the increased prevalence of autism.125 However, no children with autism have been reported to have an abnormal body burden of mercury or an excess of mercury in hair, urine, or blood.126 Neither the clinical signs and symptoms of mercury-induced neurologic damage nor the neuropathologic changes associated with mercury exposure parallel the clinical signs and symptoms of autism.20 Population-based studies have also shown that the risk of autism in children given thimerosal-containing vaccines is no different from that in children given thimerosal-free vaccines.20, 127 Further, since thimerosal was removed from childhood vaccines in Denmark in 1992, the incidence of autism in that country has continued to rise.128 Despite this overwhelming scientific evidence, some children with autism are receiving treatment with chelating agents.129 However, even if exposure to mercury or other heavy metals was causative of autism, chelation therapy has not been found to improve the neurodevelopmental sequelae of heavy metal toxicity.130 Also, children being treated with chelating agents are at risk of renal and hepatic toxic adverse effects.129
There have been concerns about the potential role of the measles-mumps-rubella (MMR) vaccine in the causation of autism, based on findings that have been partially retracted.131 This theory hypothesizes that the MMR vaccine produces enterocolitis, causing "leaky gut," which then leads to increased absorption of peptides with bioactive properties of endogenous opioids that produce the symptoms of autism.123 However, large-scale epidemiologic studies have failed to show an association between the MMR vaccine and autism.1, 132-135 Furthermore, a dramatically increased incidence of autism has been associated with the withdrawal of the MMR vaccine in Japan.135 Despite strong evidence against an association between either thimerosal or MMR vaccines and autism, fear generated by these scientifically disproved theories may be leading more parents to decline to have their children immunized.136
作者: binfeng2000 时间: 2008-7-31 14:23 标题: re:The leaky gut hypoth... The leaky gut hypothesis has also led to unproved claims that variants of celiac disease, yeast overgrowth, and immunologic abnormalities can cause autism.123, 129 Many children with autism have been given very restrictive gluten- and casein-free diets because of unfounded fears that opioidlike peptides derived from gluten and casein are absorbed through their leaky guts and can be detected in their urine. However, children with autism have not been found to have an increased rate of celiac disease and do not have excessive amounts of opioidlike compounds in their urine.137-142
Although hypothesized as another cause of leaky gut, fungal overgrowth in the intestines has not been documented at endoscopy in children with autism.143 While there is no evidence that systemic antifungal medications improve autistic behavior, these medications are associated with liver toxicity, anemia, diarrhea, and exfoliative dermatitis.123, 129
It has been hypothesized that autism is an autoimmune disorder; however, treatment with intravenous immunoglobulin has not proved effective.144 The pancreatic hormone secretin has also been proposed as a treatment of autism. However, more than a dozen published, peer-reviewed, randomized, double-blind, placebo-controlled trials have failed to show secretin to be effective in treating the symptoms of autism.129 Other medical therapies that have been recommended but that do not have sufficient evidence to support their effectiveness or safety include vitamin and mineral supplements (vitamin B6 and magnesium, vitamin C, vitamin B12, and folic acid), amino acid and peptide supplements (dimethyl glycine and carnosine), and -3 long-chain polyunsaturated fatty acids.129
Clinicians should counsel parents of children with autism to be sure that any treatment they may consider is supported by evidence from randomized, double-blind, placebo-controlled clinical trials published in the peer-reviewed medical literature. Families should be informed about potential health risks associated with unproved therapies. Finally, parents should be reminded that such treatments may take time, effort, and financial resources away from effective, evidence-based interventions.
Families that include a child with one of the ASDs experience considerable stress as they are confronted with extraordinary demands on their time, energy, and financial resources. It is essential to offer clear explanations of diagnostic findings and treatment recommendations and to guide families toward effective treatment approaches. This requires the combined effort of experts in the ASD field working collaboratively with primary care clinicians.
Parents need reliable sources of information about ASDs. This is particularly important in an era when the Internet makes misinformation as easily available as accurate information. The Web sites sponsored by the Autism Society of America (www.autism-society.org/site/PageServer), TEACCH (www.teacch.com), and the National Institute of Child Health and Human Development (www.nichd.nih.gov/publications/pubs/autismfacts.pdf) are particularly useful sources of reliable information. However, even accurate information about ASDs is subject to misinterpretation because of the inherent complexity of the topic and the many unanswered questions in the field. There is no substitute for knowledgeable professionals who provide ongoing advice in the context of regular primary care management of children with ASDs.
Correspondence: William J. Barbaresi, MD, Departments of Pediatric and Adolescent Medicine, Division of Developmental and Behavioral Pediatrics, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905 (barbaresi.william@mayo.edu).
Accepted for Publication: May 5, 2006.
Author Contributions: Study concept and design: Barbaresi, Katusic, and Voigt. Drafting of the manuscript: Barbaresi, Katusic, and Voigt. Critical revision of the manuscript for important intellectual content: Barbaresi, Katusic, and Voigt. Administrative, technical, and material support: Barbaresi, Katusic, and Voigt. Study supervision: Barbaresi.
Financial Disclosure: None reported.
作者: binfeng2000 时间: 2008-7-31 14:23 标题: re:Author Affiliations:... Author Affiliations: Departments of Pediatric and Adolescent Medicine, Division of Developmental and Behavioral Pediatrics (Drs Barbaresi and Voigt), and Health Sciences Research, Division of Epidemiology (Dr Katusic), and Mayo Clinic–Dana Child Development and Learning Disorders Program (Drs Barbaresi, Katusic, and Voigt), Mayo Clinic College of Medicine, Rochester, Minn.
1. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. The incidence of autism in Olmsted County, Minnesota, 1976-1997: results from a population-based study. Arch Pediatr Adolesc Med. 2005;159:37-44. FREE FULL TEXT
2. Stratton K, ed, Gable A, ed, Shetty P, ed, McCormich M, ed. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: National Academy Press; 2001.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
4. Kanner L. Autistic disturbances of affective contact. Nervous Child. 1943;2:217-250.
5. New York State Department of Health Early Intervention Program. Clinical Practice Guideline: Report of the Recommendations, Autism/Pervasive Developmental Disorders. Albany: New York State Dept of Health, Health Education Services; 1999.
6. Lord C, Risi S. Frameworks and methods in diagnosing autism spectrum disorders. Ment Retard Dev Disabil Res Rev. 1998;4:90-96. FULL TEXT | ISI
7. Filipek PA, Accardo PJ, Baranek GT, et al. The screening and diagnosis of autistic spectrum disorders [published correction appears in J Autism Dev Disord. 2000;30:81]. J Autism Dev Disord. 1999;29:439-484. FULL TEXT | ISI | PUBMED
8. Lord C, Volkmar F. Genetics of childhood disorders, XLII: autism, part 1: diagnosis and assessment in autistic spectrum disorders. J Am Acad Child Adolesc Psychiatry. 2002;41:1134-1136. FULL TEXT | ISI | PUBMED
9. Wing L, Gould J. Severe impairments of social interaction and associated abnormalities in children: epidemiology and classification. J Autism Dev Disord. 1979;9:11-29. FULL TEXT | ISI | PUBMED
10. Beglinger L, Smith T. Concurrent validity of social subtype and IQ after early intensive behavioral intervention in children with autism: a preliminary investigation. J Autism Dev Disord. 2005;35:295-303. FULL TEXT | ISI | PUBMED
11. Volkmar F, Chawarska K, Klin A. Autism in infancy and early childhood. Annu Rev Psychol. 2005;56:315-336. FULL TEXT | ISI | PUBMED
12. Volkmar FR, Lord C, Bailey A, Schultz RT, Klin A. Autism and pervasive developmental disorders. J Child Psychol Psychiatry. 2004;45:135-170. FULL TEXT | ISI | PUBMED
13. Wing L, Potter D. The epidemiology of autistic spectrum disorders: is the prevalence rising? Ment Retard Dev Disabil Res Rev. 2002;8:151-161. FULL TEXT | ISI | PUBMED
14. Fombonne E, Simmons H, Ford T, Meltzer H, Goodman R. Prevalence of pervasive developmental disorder in the British nationwide survey of child mental health. J Am Acad Child Adolesc Psychiatry. 2001;40:820-827. FULL TEXT | ISI | PUBMED
15. Fombonne E. The prevalence of autism. JAMA. 2003;289:87-89. FREE FULL TEXT
16. Yeargin-Allsopp M, Rice C, Karapurkar T, Doernberg N, Boyle C, Murphy C. Prevalence of autism in a US metropolitan area. JAMA. 2003;289:49-55. FREE FULL TEXT
17. Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, Decoufle P. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics. 2001;108:1155-1161. FREE FULL TEXT
18. Gernsbacher M, Dawson M, Goldsmith H. Three reasons not to believe in an autism epidemic. Curr Dir Psychol Sci. 2005;14:55-58. FULL TEXT
19. Newschaffer CJ, Falb MD, Gurney JG. National autism prevalence trends from United States special education data. Pediatrics. 2005;115:e277-e282. FREE FULL TEXT
20. Nelson KB, Bauman ML. Thimerosal and autism? Pediatrics. 2003;111:674-679. FREE FULL TEXT
21. Smeeth L, Cook C, Fombonne PE, et al. Rate of first recorded diagnosis of autism and other pervasive developmental disorders in United Kingdom general practice, 1988 to 2001. BMC Med. 2004;2:39. FULL TEXT | PUBMED
22. Lipkin PH, Schertz M. An assessment of the efficacy of early intervention programs. In: Capute AJ, Accardo PJ, eds. Developmental Disabilities in Infancy and Childhood. 2nd ed. Baltimore, Md: Brookes Publishing Co; 1996:525-547.
23. American Academy of Pediatrics,; Council on Children with Disabilities. Identifying infants and young children with developmental disorders in the medical home: an algorithm for developmental surveillance and screening. Pediatrics. 2006;118:405-420. FREE FULL TEXT
24. American Academy of Pediatrics, Committee on Children with Disabilities. The pediatrician's role in the diagnosis and management of autistic spectrum disorder in children. Pediatrics. 2001;107:1221-1226. FREE FULL TEXT
25. Baron-Cohen S, Allen J, Gillberg C. Can autism be detected at 18 months? the needle, the haystack, and the CHAT. Br J Psychiatry. 1992;161:839-843. FREE FULL TEXT
26. Baron-Cohen S, Wheelwright S, Cox A, et al. Early identification of autism by the CHecklist for Autism in Toddlers (CHAT). J R Soc Med. 2000;93:521-525. FREE FULL TEXT
27. Berument SK, Rutter M, Lord C, Pickles A, Bailey A. Autism screening questionnaire: diagnostic validity. Br J Psychiatry. 1999;175:444-451. FREE FULL TEXT
28. Rutter M, Bailey A, Lord C. SCQ: Social Communication Questionnaire. Los Angeles, Calif: Western Psychological Services; 2003.
29. Osterling J, Dawson G. Early recognition of children with autism: a study of first birthday home videotapes. J Autism Dev Disord. 1994;24:247-257. FULL TEXT | ISI | PUBMED
30. Mars AE, Mauk JE, Dowrick P. Symptoms of pervasive developmental disorders as observed in prediagnostic home videos of infants and toddlers. J Pediatr. 1998;132:500-504. FULL TEXT | ISI | PUBMED
31. Werner E, Dawson G, Osterling J, Dinno N. Brief report: recognition of autism spectrum disorder before one year of age: a retrospective study based on home videotapes. J Autism Dev Disord. 2000;30:157-162. FULL TEXT | ISI | PUBMED
32. Baranek GT. Autism during infancy: a retrospective video analysis of sensory-motor and social behaviors at 9-12 months of age. J Autism Dev Disord. 1999;29:213-224. FULL TEXT | ISI | PUBMED
33. Baird G, Charman T, Baron-Cohen S, et al. A screening instrument for autism at 18 months of age: a 6-year follow-up study. J Am Acad Child Adolesc Psychiatry. 2000;39:694-702. FULL TEXT | ISI | PUBMED
34. Chouieri R, Bridgemohan C. To make the biggest difference, screen early for autism spectrum disorders. Contemp Pediatr. 2005;22:54-64.
35. Robins DL, Fein D, Barton ML, Green JA. The modified checklist for autism in toddlers: an initial study investigating the early detection of autism and pervasive developmental disorders. J Autism Dev Disord. 2001;31:131-144. FULL TEXT | ISI | PUBMED
36. Dumont-Mathieu T, Fein D. Screening for autism in young children: the Modified Checklist for Autism in Toddlers (M-CHAT) and other measures. Ment Retard Dev Disabil Res Rev. 2005;11:253-262. FULL TEXT | ISI | PUBMED
37. Siegel B. Pervasive Developmental Disorders Screening Test—II. San Antonio, Tex: Harcourt Assessment Inc; 2004.
38. Stone WL, Coonrod EE, Turner LM, Pozdol SL. Psychometric properties of the STAT for early autism screening. J Autism Dev Disord. 2004;34:691-701. FULL TEXT | ISI | PUBMED
39. Lockyer L, Rutter M. A five- to fifteen-year follow-up study of infantile psychosis, IV: Patterns of cognitive ability. Br J Soc Clin Psychol. 1970;9:152-163. ISI | PUBMED
40. Happe FGE. Wechsler IQ profile and theory of mind in autism: a research note. J Child Psychol Psychiatry. 1994;35:1461-1471. ISI | PUBMED
41. Dennis M, Lockyer L, Lazenby AL, Donnelly RE, Wilkinson M, Schoonheyt W. Intelligence patterns among children with high-functioning autism, phenylketonuria, and childhood head injury. J Autism Dev Disord. 1999;29:5-17. FULL TEXT | ISI | PUBMED
42. Joseph RM, Tager-Flusberg H, Lord C. Cognitive profiles and social-communicative functioning in children with autism spectrum disorder. J Child Psychol Psychiatry. 2002;43:807-821. FULL TEXT | ISI | PUBMED
43. Ehlers S, Nyden A, Gillberg C, et al. Asperger syndrome, autism, and attention disorders: a comparative study of the cognitive profiles of 120 children. J Child Psychol Psychiatry. 1997;38:207-217. ISI | PUBMED
44. Klin A, Volkmar FR, Sparrow SS, Cicchetti DV, Rourke BP. Validity and neuropsychological characterization of Asperger syndrome: convergence with nonverbal learning disabilities syndrome. J Child Psychol Psychiatry. 1995;36:1127-1140. ISI | PUBMED
45. Mayes SD, Calhoun SL. Similarities and differences in Wechsler intelligence Scale for Children, third edition (WISC-III) profiles: support for subtest analysis in clinical referrals. Clin Neuropsychol. 2004;18:559-572. FULL TEXT | ISI | PUBMED
46. Mayes SD, Calhoun SL. Ability profiles in children with autism: influence of age and IQ. Autism. 2003;7:65-80. ABSTRACT
47. Mayes SD, Calhoun SL. Analysis of WISC-II, Stanford–Binet IV, and academic achievement test scores in children with autism. J Autism Dev Disord. 2003;33:329-341. FULL TEXT | ISI | PUBMED
48. Shah A, Frith U. Why do autistic individuals show superior performance on the block design task? J Child Psychol Psychiatry. 1993;34:1351-1364. ISI | PUBMED
49. Voigt RG, Childers DO, Dickerson CL, et al. Early pediatric neurodevelopmental profile of children with autistic spectrum disorders. Clin Pediatr (Phila). 2000;39:663-668. FREE FULL TEXT
50. Voigt RG. The Capute Scales in research. In: Accardo PJ, Capute AJ, eds. The Capute Scales. Baltimore, Md: Brookes Publishing Co; 2005:41-46.
51. Accardo PJ, ed, Capute AJ, ed. The Capute Scales. Baltimore, Md: Brookes Publishing Co; 2005.
52. Lord C, McGee JP, eds, for the Committee on Educational Interventions for Children with Autism, Division of Behavioral and Social Sciences and Education, National Research Council. Educating Children With Autism. Washington, DC: National Academy Press; 2001.
53. Individuals with Education Disabilities Act, Public Law 105-117 (1997).
54. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview–Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24:659-685. FULL TEXT | ISI | PUBMED
55. Klinger LG, Renner P. Performance-based measures in autism: implications for diagnosis, early detection, and identification of cognitive profiles. J Clin Child Psychol. 2000;29:479-492. FULL TEXT | ISI | PUBMED
56. Lord C, Pickles A, McLennan J, et al. Diagnosing autism: analyses of data from the Autism Diagnostic Interview. J Autism Dev Disord. 1997;27:501-517. FULL TEXT | ISI | PUBMED
57. Lord C, Risi S, Lambrecht L, et al. The Autism Diagnostic Observation Schedule–Generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30:205-223. FULL TEXT | ISI | PUBMED
58. Gilliam J. Gilliam Autism Rating Scale (GARS). Austin, Tex: PRO-ED, Inc; 1995.
59. Schopler E, Reichler R, Rochen-Renner B. The Childhood Autism Rating Scale (CARS). Los Angeles, Calif: Western Psychological Services; 1988.
60. Bayley N. Bayley Scale of Infant Development. 2nd ed. San Antonio, Tex: Psychological Corp; 1993.
61. Mullen E. Mullen Scales of Early Learning. Los Angeles, Calif: Western Psychological Services; 1997.
62. Elliot C. Differential Abilities Scale (DAS). New York, NY: Psychological Corp; 1990.
63. Thorndike R, Hagen E, Sattler J. The Stanford-Binet Intelligence Scale: Guide for Administering and Scoring. 4th ed. Chicago, Ill: Riverside Publishing Co; 1986.
64. Wechsler D. Wechsler Intelligence Scale for Children. 4th ed. San Antonio, Tex: Psychological Corp; 2003.
65. Wechsler D. Wechsler Adult Intelligence Scale . 3rd ed. San Antonio, Tex: Psychological Corp; 1997.
66. Roid G, Miller L. Leiter International Performance Scale-Revised. Wood Dale, Ill: Stoelting Co; 1997.
67. Stutsman R. The Merrill-Palmer Scale of Mental Tests. Chicago, Ill: Stoelting Co; 1948.
68. Sparrow S, Balla D, Cicchetti D. Vineland Adaptive Behavior Scales, Expanded Edition. Circle Pines, Minn: American Guidance Service; 1984.
69. Bruininks R, Woodcock R, Weatherman R, Hill B. Scales of Independent Behavior–Revised (SIB-R). Chicago, Ill: Riverside Publishing Co; 1996.
70. Shannon M, Graef J. Lead intoxication in children with pervasive developmental disorders. J Toxicol Clin Toxicol. 1996;34:177-181. ISI | PUBMED
71. Gillberg C, Coleman M. Autism and medical disorders: a review of the literature. Dev Med Child Neurol. 1996;38:191-202. ISI | PUBMED
72. Challman TD, Barbaresi WJ, Katusic SK, Weaver A. The yield of the medical evaluation of children with pervasive developmental disorders. J Autism Dev Disord. 2003;33:187-192. FULL TEXT | ISI | PUBMED
73. Voigt RG, Dickerson CL, Reynolds AM, Childers DO, Rodriguez DL, Brown FR. Laboratory evaluation of children with autistic spectrum disorders: a guide for primary care pediatricians. Clin Pediatr (Phila). 2000;39:669-671. FREE FULL TEXT
74. Shevell MI, Majnemer A, Rosenbaum P, Abrahamowicz M. Etiologic yield of autistic spectrum disorder: a prospective study. J Child Neurol. 2001;16:509-512. ISI | PUBMED
75. Chudley AE, Gutierrez E, Jocelyn LJ, Chodirker BN. Outcomes of genetic evaluation in children with pervasive developmental disorder. J Dev Behav Pediatr. 1998;19:321-325. ISI | PUBMED
76. Kielinen M, Rantala H, Timonen E, Linna SL, Moilanen I. Associated medical disorders and disabilities in children with autistic disorder: a population-based study. Autism. 2004;8:49-60. ABSTRACT
77. Kosinovsky B, Hermon S, Yoran-Hegesh R, et al. The yield of laboratory investigations in children with infantile autism. J Neural Transm. 2005;112:587-596. FULL TEXT | ISI | PUBMED
78. Curatolo P, Porfirio MC, Manzi B, Seri S. Autism in tuberous sclerosis. Eur J Paediatr Neurol. 2004;8:327-332. FULL TEXT | ISI | PUBMED
79. Redcay E, Courchesne E. When is the brain enlarged in autism? a meta-analysis of all brain size reports. Biol Psychiatry. 2005;58:1-9. FULL TEXT | ISI | PUBMED
80. Boddaert N, Zilbovicius M. Functional neuroimaging and childhood autism. Pediatr Radiol. 2002;32:1-7. FULL TEXT | ISI | PUBMED
81. Herbert MR, Ziegler DA, Deutsch CK, et al. Brain asymmetries in autism and developmental language disorder: a nested whole-brain analysis. Brain. 2005;128:213-226. FREE FULL TEXT
82. Rapin I. Autism. N Engl J Med. 1997;337:97-104. FREE FULL TEXT
83. Cohen D, Pichard N, Tordjman S, et al. Specific genetic disorders and autism: clinical contribution towards their identification. J Autism Dev Disord. 2005;35:103-116. FULL TEXT | ISI | PUBMED
84. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics. 2004;113:e472-e486. FREE FULL TEXT
85. Wassink TH, Brzustowicz LM, Bartlett CW, Szatmari P. The search for autism disease genes. Ment Retard Dev Disabil Res Rev. 2004;10:272-283. FULL TEXT | ISI | PUBMED
86. Dykens EM, Sutcliffe JS, Levitt P. Autism and 15Q11-Q13 disorders: behavioral, genetic, and pathophysiological issues. Ment Retard Dev Disabil Res Rev. 2004;10:284-291. FULL TEXT | ISI | PUBMED
87. Carney RM, Wolpert CM, Ravan SA, et al. Identification of MeCP2 mutations in a series of females with autistic disorder. Pediatr Neurol. 2003;28:205-211. ISI | PUBMED
88. Rutter M, Bailey A, Bolton P, Le Couteur A. Autism and known medical conditions: myth and substance. J Child Psychol Psychiatry. 1994;35:311-322. ISI | PUBMED
89. Baieli S, Pavone L, Meli C, Fiumara A, Coleman M. Autism and phenylketonuria. J Autism Dev Disord. 2003;33:201-204. FULL TEXT | ISI | PUBMED
90. Gorker I, Tuzun U. Autistic-like findings associated with a urea cycle disorder in a 4-year-old girl. J Psychiatry Neurosci. 2005;30:133-135. ISI | PUBMED
91. Kohler M, Assmann B, Brautigam C, et al. Adenylosuccinase deficiency: possibly under diagnosed encephalopathy with variable clinical features. Eur J Paediatr Neurol. 1999;3:3-6. FULL TEXT | PUBMED
92. Tierney E, Nwokoro NA, Kelley RI. Behavioral phenotype of RSH/Smith-Lemli-Opitz syndrome. Ment Retard Dev Disabil Res Rev. 2000;6:131-134. FULL TEXT | ISI | PUBMED
93. Oliveira G, Diogo L, Grazina M, et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev Med Child Neurol. 2005;47:185-189. FULL TEXT | ISI | PUBMED
94. Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol. 2002;1:352-358. FULL TEXT | ISI | PUBMED
95. Olsson I, Steffenburg S, Gillberg C. Epilepsy in autism and autistic-like conditions: a population-based study. Arch Neurol. 1988;45:666-668. ABSTRACT
96. Tuchman RF, Rapin I. Regression in pervasive developmental disorders: seizures and epileptiform electroencephalogram correlates. Pediatrics. 1997;99:560-566. FREE FULL TEXT
97. Scott RC, Neville BG. Developmental perspectives on epilepsy. Curr Opin Neurol. 1998;11:115-118. FULL TEXT | ISI | PUBMED
98. Nass R, Petrucha D. Acquired aphasia with convulsive disorder: a pervasive developmental disorder variant. J Child Neurol. 1990;5:327-328. ISI | PUBMED
99. Lewine JD, Andrews R, Chez M, et al. Magnetoencephalographic patterns of epileptiform activity in children with regressive autism spectrum disorders. Pediatrics. 1999;104:405-418. FREE FULL TEXT
100. Rogers SJ. Empirically supported comprehensive treatments for young children with autism. J Clin Child Psychol. 1998;27:168-179. FULL TEXT | ISI | PUBMED
101. Lovaas OI. Teaching Individuals With Developmental Delays: Basic Intervention Techniques. Austin, Tex: PRO-ED, Inc; 2003.
102. Lovaas OI. Behavioral treatment and normal educational and intellectual functioning in young autistic children. J Consult Clin Psychol. 1987;55:3-9. FULL TEXT | ISI | PUBMED
103. McEachin JJ, Smith T, Lovaas OI. Long-term outcome for children with autism who received early intensive behavioral treatment. Am J Ment Retard. 1993;97:359-372. ISI | PUBMED
104. Schopler E, Short A, Mesibov G. Relation of behavioral treatment to "normal functioning": comment on Lovaas. J Consult Clin Psychol. 1989;57:162-164. FULL TEXT | ISI | PUBMED
105. Smith T, Eikeseth S, Klevstrand M, Lovaas O. Intensive behavioral treatment for preschoolers with severe mental retardations and pervasive developmental disorder. Am J Ment Retard. 1997;102:238-249. FULL TEXT | ISI | PUBMED
106. Sheinkopf SJ, Siegel B. Home-based behavioral treatment of young children with autism. J Autism Dev Disord. 1998;28:15-23. FULL TEXT | ISI | PUBMED
107. Eikeseth S, Smith T, Jahr E, Eldevik S. Intensive behavioral treatment at school for 4- to 7-year-old children with autism: a 1-year comparison controlled study. Behav Modif. 2002;26:49-68. FREE FULL TEXT
108. Howard JS, Sparkman CR, Cohen HG, Green G, Stanislaw H. A comparison of intensive behavior analytic and eclectic treatments for young children with autism. Res Dev Disabil. 2005;26:359-383. FULL TEXT | ISI | PUBMED
109. Mesibov G, Shea V, Schopler E. The TEACCH Approach to Autism Spectrum Disorders. New York, NY: Springer; 2005.
110. Mesibov G. Formal and informal measures on the effectiveness of the TEACCH programme. Autism. 1997;1:25-35. ABSTRACT
111. Mostert MP. Facilitated communication since 1995: a review of published studies. J Autism Dev Disord. 2001;31:287-313. FULL TEXT | ISI | PUBMED
112. American Academy of Pediatrics, Committee on Children With Disabilities. Auditory integration training and facilitated communication for autism. Pediatrics. 1998;102:431-433. FREE FULL TEXT
113. Mudford OC, Cross BA, Breen S, et al. Auditory integration training for children with autism: no behavioral benefits detected. Am J Ment Retard. 2000;105:118-129. FULL TEXT | ISI | PUBMED
114. Sinha Y, Silove N, Wheeler D, Williams K. Auditory integration training and other sound therapies for autism spectrum disorders. Cochrane Database Syst Rev. 2004;1:CD003681. PUBMED
115. Dawson G, Watling R. Interventions to facilitate auditory, visual, and motor integration in autism: a review of the evidence. J Autism Dev Disord. 2000;30:415-421. FULL TEXT | ISI | PUBMED
116. Aman MG, Novotny S, Samango-Sprouse C, et al. Outcome measures for clinical drug trials in autism. CNS Spectr. 2004;9:36-47. ISI | PUBMED
117. McCracken JT, McGough J, Shah B, et al, Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314-321. FREE FULL TEXT
118. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62:1266-1274. FREE FULL TEXT
119. DeLong GR, Teague LA, McSwain Kamran M. Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol. 1998;40:551-562. ISI | PUBMED
120. Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992;12:322-327. ISI | PUBMED
121. Steingard R, Biederman J. Lithium responsive manic-like symptoms in two individuals with autism and mental retardation. J Am Acad Child Adolesc Psychiatry. 1987;26:932-935. ISI | PUBMED
122. American Academy of Pediatrics, Committee on Children With Disabilities. Technical report: the pediatrician's role in diagnosis and management of autistic spectrum disorder in children. Pediatrics. 2001;107:1221-1226. http://www.pediatrics.org/cgi/content/full/107/5/e85. Accessed October 1, 2005.
123. Hyman SL, Levy SE. Autistic spectrum disorders: when traditional medicine is not enough. Contemp Pediatr. 2000;17:101-116.
124. Kaptchuk TJ, Eisenberg DM. The persuasive appeal of alternative medicine. Ann Intern Med. 1998;129:1061-1065. FREE FULL TEXT
125. Bernard S, Enayati A, Redwood L, Roger H, Binstock T. Autism: a novel form of mercury poisoning. Med Hypotheses. 2001;56:462-471. FULL TEXT | ISI | PUBMED
126. Aschner M, Walker SJ. The neuropathogenesis of mercury toxicity. Mol Psychiatry. 2002;7(suppl 2):S40-S41.
127. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA. 2003;290:1763-1766. FREE FULL TEXT
128. Madsen KM, Lauritsen MB, Pedersen CB, et al. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics. 2003;112:604-606. FREE FULL TEXT
129. Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev. 2005;11:131-142. FULL TEXT | ISI | PUBMED
130. Dietrich KN, Ware HH, Salganik M, et al. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics. 2004;114:19-24. FREE FULL TEXT
131. Wakefield AJ, Murch SH, Anthony A. Ileal lymphoid nodular hyperplasia, non-specific colitis, and pervasive developmental disorder. Lancet. 1998;351:637-641. FULL TEXT | ISI | PUBMED
132. Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. JAMA. 2001;285:1183-1185. FREE FULL TEXT
133. Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002;347:1477-1482. FREE FULL TEXT
134. Taylor B, Lingam R, Simmons A, Stowe J, Miller E, Andrews N. Autism and MMR vaccination in North London: no causal relationship. Mol Psychiatry. 2002;7(suppl 2):S7-S8. PUBMED
135. Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. J Child Psychol Psychiatry. 2005;46:572-579. FULL TEXT | ISI | PUBMED
136. Paterson R. MMR debate fall-out continues. Lancet Infect Dis. 2004;4:653. ISI | PUBMED
137. Pavone L, Fiumara A, Bottaro G, Mazzone D, Coleman M. Autism and celiac disease: failure to validate the hypothesis that a link might exist. Biol Psychiatry. 1997;42:72-75. FULL TEXT | ISI | PUBMED
138. Kuddo T, Nelson KB. How common are gastrointestinal disorders in children with autism? Curr Opin Pediatr. 2003;15:339-343. FULL TEXT | ISI | PUBMED
139. Black C, Kaye JA, Jick H. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. BMJ. 2002;325:419-421. FREE FULL TEXT
140. Hunter LC, O'Hare A, Herron WJ, Fisher LA, Jones GE. Opioid peptides and dipeptidyl peptidase in autism. Dev Med Child Neurol. 2003;45:121-128. ISI | PUBMED
141. Williams KM, Marshall T. Urinary protein patterns in autism as revealed by high resolution two-dimensional electrophoresis. Biochem Soc Trans. 1992;20:189S. PUBMED
142. Le Couteur A, Trygstad O, Evered C, Gillberg C, Rutter M. Infantile autism and urinary excretion of peptides and protein-associated peptide complexes. J Autism Dev Disord. 1988;18:181-190. FULL TEXT | ISI | PUBMED
143. Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999;135:559-563. FULL TEXT | ISI | PUBMED
144. DelGiudice-Asch G, Simon L, Schmeidler J, Cunningham-Rundles C, Hollander E. A pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord. 1999;29:157-160. FULL TEXT | ISI | PUBMED